Evidence map›Paper›PMID 40703204›Full record

ArticleNeurology. Genetics2025

Combating Genetic Heterogeneity for Polygenic Prediction of Susceptibility to Brain β-Amyloid Deposition: Beyond

Vijay K Ramanan, Michael G Heckman, Ekaterina I Hofrenning, Scott A Przybelski, Jonathan Graff-Radford, Val J Lowe, Mary M Machulda, Melissa E Murray, Alicia Algeciras-Schimnich, Daniel J Figdore and 7 more

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology. Genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. More ThanNeurology. Genetics · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Vijay K RamananDepartment of Neurology, Mayo Clinic Rochester, Rochester, MN.ORCID https://orcid.org/0000-0001-6591-8734
Michael G HeckmanDepartment of Quantitative Health Sciences, Mayo Clinic Jacksonville, Jacksonville, FL.ORCID https://orcid.org/0000-0003-3770-9331
Ekaterina I HofrenningDepartment of Quantitative Health Sciences, Mayo Clinic Rochester, Rochester, MN.ORCID https://orcid.org/0000-0003-2266-6746
Scott A PrzybelskiDepartment of Quantitative Health Sciences, Mayo Clinic Rochester, Rochester, MN.ORCID https://orcid.org/0009-0009-3437-3773
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic Rochester, Rochester, MN.ORCID https://orcid.org/0000-0003-2770-0691
Val J LoweDepartment of Radiology, Mayo Clinic Rochester, Rochester, MN.ORCID https://orcid.org/0000-0002-5612-1667
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic Rochester, Rochester, MN.ORCID https://orcid.org/0000-0003-4834-5967
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL.ORCID https://orcid.org/0000-0001-7379-2545
Alicia Algeciras-SchimnichDepartment of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN.ORCID https://orcid.org/0000-0002-4455-6217
Daniel J FigdoreDepartment of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN.ORCID https://orcid.org/0000-0002-4776-3203
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL; and.ORCID https://orcid.org/0000-0003-3689-554X
David S KnopmanDepartment of Neurology, Mayo Clinic Rochester, Rochester, MN.ORCID https://orcid.org/0000-0002-6544-066X
Clifford R JackDepartment of Radiology, Mayo Clinic Rochester, Rochester, MN.ORCID https://orcid.org/0000-0001-7916-622X
Ronald C PetersenDepartment of Neurology, Mayo Clinic Rochester, Rochester, MN.ORCID https://orcid.org/0000-0002-8178-6601
Owen A RossDepartments of Neuroscience and Clinical Genomics, Mayo Clinic Jacksonville, Jacksonville, FL.ORCID https://orcid.org/0000-0003-4813-756X
Prashanthi VemuriDepartment of Radiology, Mayo Clinic Rochester, Rochester, MN.ORCID https://orcid.org/0000-0003-4286-0589
Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Investigating Resistance and Resilience Mechanisms in Alzheimer’s DiseaseR01AG056366 · NIA · MAYO CLINIC ROCHESTER · PI PRASHANTHI VEMURI · 2017 to 2026
$7.0M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
NIA NIH HHS R01 AG056366NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Background and Objectives: The Methods: We analyzed data from the Mayo Clinic Study of Aging (MCSA), Alzheimer's Disease Neuroimaging Initiative (ADNI), and Rush Religious Orders Study and Memory and Aging Project. Frequency of Results: The GWAS identified previously implicated (e.g., Discussion: Our non-

Identifiers

PMID40703204
PMCPMC12285673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.